Metformin treatment and its effect on survival in patients with type 2 diabetes mellitus

Authors: Andrej Dukát 1;  Juraj Payer 1;  Ján Kyselovič 1;  Milan Kriška 2;  Patrik Valent 1;  Peter Jackuliak 1
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava 1;  Ústav farmakológie a klinickej farmakológie LF UK v Bratislave 2
Published in: Forum Diab 2023; 12(3): 103-105
Category: Review Article


Longitudinal monitoring of metformin treatment of patients with type-2 diabetes mellitus leads to the improvement of their survival. Multicentric follow-up in four centers of the United Kingdom during years 2016–2021 evaluated coronary microvascular function in relation to the metformin therapy. Significant improvement of myocardial perfusion reserve lead to better prognosis of the patients with type-2 diabetes mellitus. Measurement of myocardial perfusion reserve is the better measure for endothelial function, than myocardial perfusion flow.


metformin – mellitus – microcirculation – myocardial function – prognosis

  1. Sharrack N, Knott KD, Gulsin GS et al. Metformin associates with improved myocardial perfusion reserve and survival in patients with type 2 diabetes mellitus. Dostupné z DOI: <>.
  2. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11(11): 1278–1289. Dostupné z DOI: <>.
  3. Larghat AM, Swoboda PP, Biglands JD et al. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 2014; 15(12): 1368–1376. Dostupné z DOI: <>.
  4. Levelt E, Piechnik SK, Liu A et al. Adenosine stress CMR T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus without obstructive coronary artery disease. J Cardiovasc Magn Reson 2017; 19(1): 81. Dostupné z DOI: <–017–0397–8>.
  5. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137(1): 25–33. Dostupné z DOI: <–4819–137–1-200207020–00009>.
  6. Dukát A, Kriška M, Kyselovič J, Payer J. Fibrilácia predsiení a liečba metformínom. Forum Diab 2023; 12(1): 52–54.
  7. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37(5): 1344–1350. Dostupné z DOI: <–1097(01)01129–9>.
  8. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558.
  9. Johnson JA, Majumdar SR, Simpson SH et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25(12): 2244–2248. Dostupné z DOI: <>.
  10. Vitale C, Mercuro G, Cornoldi A et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258(3): 250–256. Dostupné z DOI: <–2796.2005.01531.x>.
  11. Kao J, Tobis J, McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004; 93(11): 1347–1350. Dostupné z DOI: <>.
  12. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765–1772. Dostupné z DOI: <–6736(09)60697–8>.
  13. Han Y, Xie H, Liu Y et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 2019; 18(1): 96. Dostupné z DOI: <–019–0900–7>.
  14. Dziubak A, Wojcicka G, Wojtak A et al. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018; 19(10): 2869. Dostupné z DOI: <>.
  15. Gundewar S, Calvert JW, Jha S et al. Activation of AMP-activated protein kinase by metfomin improves left ventricular function and survival in heart failure. Circ Res 2009; 104(3): 403–411. Dostupné z DOI: <>.
  16. Breining P, Jensen JB, Sundelin EI et al. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes Obes Metab 2018; 20(9): 2264–2273. Dostupné z DOI: <>.
  17. Neven E, Vervaet B, Brand K et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone dis­order. Kidney Int 2018; 94(1): 102–113. Dostupné z DOI: <>.
  18. Bhat A, Sebastiani G, Bhat M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol 2015; 7(12): 1652–1659. Dostupné z DOI: <>.
  19. Gandini S, Puntoni M, Heckman-Stoddard BM et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 2014; 7(9): 867–885. Dostupné z DOI: <–6207.CAPR-13–0424>.
  20. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med 2015; 66: 17–29. Dostupné z DOI: <–093128>.
Diabetology Endocrinology Internal medicine
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account